Apellis Pharmaceuticals Announces Proposed Public Offering of Common Stock

NEXT STORY
Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
PREV STORY
10x Genomics to Present at the 38th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

FDA Advisory Committee Votes 12-2 in Favor of the Safety and Effectiveness of Insmed’s ALIS for the Treatment of NTM Lung Disease Caused by MAC for Adult Patients with Limited or No Treatment Options

--Advisory committee supports surrogate endpoint of sputum culture conversion-- --ALIS currently under FDA Priority ...

author_avatar
NASDAQ Market News

G1 Therapeutics Makes Key Appointments to Management Team

Terry Murdock appointed Senior Vice President, Development OperationsShannon Morris, MD, PhD, named Vice President, ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Reports Second Quarter 2018 Financial Results

- Continued advancement of endocrinology rare disease pipeline, paving way for application of TransCon™ ...

author_avatar
NASDAQ Market News